2.7 , has recently emerged as an useful echocardiographic measurement to refine the estimate of cardiovascular (CV) risk in ESRD. Whether progression or regression in LAV has prognostic value in patients with ESRD is still unknown. The prognostic value for CV events of changes in LAV was tested in a cohort of 191 dialysis patients. Echocardiography was performed twice, 17 ؎ 2 mo apart. Changes in LAV that occurred between the second and the first echocardiographic studies were used to predict CV events during the ensuing 27 ؎ 13 mo. During the follow-up, there was a significant increase in LAV (from 10.5 ؎ 5.0 to 11.6 ؎ 5.6 ml/m 2.7 ; P < 0.001). After the second echocardiographic study, 76 patients died (52 [68%] of CV causes) and 33 had nonfatal CV events. The independent association between changes in LAV and CV events was analyzed in a multiple Cox regression model taking into account a series of potential confounders, including baseline LAV and left ventricular mass and geometry. In these models, a 1-ml/m 2.7 per yr increase in LAV was associated with a 12% increase in the relative risk for fatal and nonfatal CV events (P < 0.001). Changes in LAV predict incident CV events in dialysis patients independent of the corresponding baseline measurement and of left ventricular mass. Monitoring LA size by echocardiography is useful for monitoring CV risk in patients with ESRD. E chocardiography is now an established technique to estimate the risk for cardiovascular (CV) complications and to guide treatment in patients with ESRD (1-4). The left atrium is an important potential risk marker because it fulfills three major physiologic roles that affect left ventricular (LV) filling and performance. Indeed, it acts as a contractile pump, as a reservoir that collects pulmonary venous return, and as a conduit for the passage of stored blood from the left atrium to the left ventricle during early ventricular diastole. Although no specific recommendation can be extrapolated to ESRD, current guidelines in the general population jointly issued by the American College of Cardiology, the American Heart Association, and the European Society of Cardiology (5) consider the measurement of left atrial volume (LAV) as clinically relevant information and emphasize that an increased LAV is associated with adverse CV outcomes (6 -8).
chocardiography is now an established technique to estimate the risk for cardiovascular (CV) complications and to guide treatment in patients with ESRD (1) (2) (3) (4) . The left atrium is an important potential risk marker because it fulfills three major physiologic roles that affect left ventricular (LV) filling and performance. Indeed, it acts as a contractile pump, as a reservoir that collects pulmonary venous return, and as a conduit for the passage of stored blood from the left atrium to the left ventricle during early ventricular diastole. Although no specific recommendation can be extrapolated to ESRD, current guidelines in the general population jointly issued by the American College of Cardiology, the American Heart Association, and the European Society of Cardiology (5) consider the measurement of left atrial volume (LAV) as clinically relevant information and emphasize that an increased LAV is associated with adverse CV outcomes (6 -8) .
Left ventricular mass index (LVMI) (3, 9) and indicators of LV contractility, such as ejection fraction and midwall fractional shortening (mwFS), (10) as well as LV chamber volume (11) , provide valuable information for initial risk stratification and for risk monitoring in the follow-up of dialysis patients. We recently reported that, independent of these indicators, the volume of the left atrium, as indexed by height 2.7 , may be useful to refine the risk estimate specifically in ESRD (12) . Indeed, the prognostic power of LAV in this population is of a degree that is comparable to that of LVMI and, when tested in models that include both measurements, it maintains an independent relationship with incident CV events (12) . As mentioned before, serial measurements of both LVMI and mwFS provide prognostic information beyond that given by single studies of these echocardiographic measurements (13, 14) . In other words, progression or regression of LVH and LV dysfunction herald changes in the risk for incident CV events, and for this reason, repeated echocardiographic studies are considered useful to monitor the evolution of cardiomyopathy in these patients. Whether progression or regression in LAV has prognostic value in patients with ESRD is still unknown. The issue is of relevance because extracellular volume overload, valvular heart disease, and alterations in LVM and compliance, all factors that impinge on LAV, are common in the dialysis population and because at least some of these factors may be modified by dialysis as well as by drug treatment. Therefore, investigating whether changes in LAV reflect changes in the risk for death and CV complications and whether these associations are independent of ongoing changes in LVM and LV function is an important question that may have clinical implications. In this prospective cohort study, we examined the prognostic power of serial measurements of LAV in dialysis patients who attended the baseline and follow-up echocardiographic measurements in Cardiovascular Risk Extended Evaluation in Dialysis Patients (CREED), a multicenter cohort study that aimed to establish the role of traditional and emerging risk factors in the high CV risk of patients with ESRD. To this aim, we related changes in LAV to all-cause mortality and incident CV events and tested whether these relationships are independent of baseline LAV, LVMI, LV systolic function, previous cardiovascular events, and a series of traditional and nontraditional risk factors in patients with ESRD.
Materials and Methods

Protocol
The protocol was in conformity to the Declaration of Helsinki, and informed consent was obtained from each participant. All studies were performed between 8 a.m. and 1 p.m.
Original Study Cohort
The original dialysis cohort was formed by 283 patients (158 men and 125 women). At enrollment, these patients had been on regular dialysis treatment for at least 6 mo (median duration of regular dialysis treatment 41 mo; interquartile range 18 to 93 mo). The enrollment criteria in this cohort were no history of congestive heart failure (defined as dyspnea in addition to two of the following conditions: Raised jugular pressure, bibasilar crackles, pulmonary venous hypertension, or interstitial edema on chest x-ray that required hospitalization or extra ultraultrafiltration [15] ), LV ejection fraction Ն35%, and no intercurrent or terminal illnesses. Thirty-four patients were excluded because of low-quality echocardiographic LAV recordings. Therefore, 249 patients (142 men and 107 women) entered this study. The main demographic and clinical characteristics of the cohort are detailed in Table 1 
Patients Who Repeated the Echocardiographic Study
Thirty-six of 249 patients who entered this study died before the time at which the second echocardiographic study was performed, five patients underwent renal transplantation, and 17 patients could not repeat echocardiography for logistic reasons. Therefore, 191 patients were left for this study (see Table 1 ). No patient had severe valvular heart disease. However, 23 patients had mild to moderate valvular heart disease: Two patients had combined valvular stenosis and insufficiency (mitral in one case and aortic in one case), five patients had isolated valvular stenosis (mitral in one case and aortic in four cases), and 16 patients had isolated valvular insufficiency (mitral in 10 cases, aortic in five cases, and a simultaneous involvement of two valves in one case).
Follow-Up
After the initial assessment, patients were followed up by the nephrologists who participated in the study. The study was purely observational; therefore, changes in treatment policy were not contemplate. The second echocardiographic study was performed from 11 to 23 mo (average 17 mo) after the baseline study. The overall duration of the follow-up was 45 Ϯ 13 mo. The duration of follow-up after the second echocardiographic study was 27 Ϯ 13 mo. Because in the present study we were interested in establishing the prognostic value of changes in LAV, all survival analyses reported herein apply to the follow-up after the second echocardiographic study (see Statistical Analyses).
Endpoint Evaluation
During the follow-up, CV events (electrocardiogram-documented anginal episodes and myocardial infarction, heart failure, electrocardiogram-documented arrhythmia, transient ischemic attacks, stroke, and other thrombotic events except arteriovenous fistula thromboses) and death were accurately recorded. Each death was reviewed and assigned an underlying cause by a panel of five physicians. As a part of the review process, all available medical information about each death was collected. This information always included study and hospitalization records. In the case of an out-of-hospital death, family members were interviewed by telephone for better ascertainment of the circumstances surrounding death. As mentioned before, for the purpose of establishing the prognostic value of progression in systolic dysfunction, only events (death and cardiovascular events) that occurred after the second echocardiogram were considered.
Echocardiography
These studies were performed midweek on a nondialysis day for hemodialysis patients and with an empty abdomen for chronic ambulatory peritoneal dialysis patients. At the time of the echocardiographic examination, investigators who were involved in echocardiographic studies were unaware of patients' clinical data. LVM was calculated according to the Devereux formula and indexed to height 2.7 (LVMI), as proposed by de Simone et al. (16) . The relative wall thickness (2 ϫ posterior wall thickness/left ventricular end diastolic diameter) was also calculated, as an index of the LV geometric pattern. Analysis of LV geometry was done according to Ganau et al. (17) . Mitral inflow was assessed with pulsed-wave Doppler echocardiography from the apical four-chamber view. LAV was calculated by the biplane method of discs (18) at the end of left ventricle systole. LAV data were analyzed as height 2.7 indexed estimates because this indexation provides the best prognostic power in dialysis patients (9) . From the mitral inflow profile, the ratio of early (E) to late atrial (A) mitral Doppler peak flow velocity (E/A ratio) was calculated as an index of LV diastolic function. mwFS, which is a reliable indicator of LV performance (interobserver reproducibility 4.0%; intraobserver reproducibility 4.5%) (19) , was calculated according to the method of Shimizu et al. (20) as described in full detail by de Simone et al. (21) . Changes in LAV were quantified by subtracting LAV at the second study from that obtained at baseline study and by factoring this difference for the time interval between the two studies.
Biochemical Measurements
Blood sampling for the measurement of routine and special biochemical measurements was performed before echocardiographic studies. The methods that were used for the determination of serum C-reactive protein (CRP) and plasma total homocysteine were detailed in a previous publication (22) .
Statistical Analyses
Data are expressed as mean Ϯ SD (normally distributed data), median and interquartile range (non-normally distributed data), or as percentage frequencies, and within-patient comparisons were made by paired t test and 2 test, as appropriate. The relationship between paired variables was analyzed by Pearson product moment correlation coefficient.
The association between changes in LAV and all-cause death and fatal and nonfatal CV events was analyzed by Kaplan-Meier analysis and by multivariate Cox's proportional hazards model. The following covariates were initially considered in the Cox survival analysis to produce a final, parsimonious model: Changes in LAV and baseline LAV; changes in E/A and the corresponding baseline value; baseline LVM and function and their changes during the follow-up; treatment modality, age, gender, diabetes, and interdialysis weight gain; baseline systolic pressure and heart rate and their changes from baseline to the follow-up visit; previous CV events and antihypertensive therapy; and smoking, serum cholesterol, hemoglobin, albumin, calcium-phosphate product and the change in these covariates at follow-up. Furthermore, we tested two emerging risk factors (CRP and homocysteine), which were available at the baseline visit only. Variables with a P Յ 0.10 were retained in the final model in which we always forced the treatment modality. By this approach, we constructed models of adequate statistical power (at least 10 events for each variable in the final model). To assess the functional form of LVMI into the survival analysis (i.e., LVMI dichotomized according to the mean, the median, and the 75th percentile of the relative data distribution), we used the Martingale residuals analysis (23) . By this analysis, we found that the "75th percentile" was the most appropriate functional form of LVMI to be considered for the stratified analysis. All calculations were made using a standard statistical package (SPSS for Windows Version 9.0.1; Chicago, IL).
Results
Demographic, anthropometric, clinical, and biochemical data of the original study cohort and of patients who repeated the echocardiographic study are summarized in Table 1 . Between the first and the second echocardiographic studies, diastolic pressure, serum albumin, and calcium-phosphate product showed a significant decrease, whereas hemoglobin and serum cholesterol increased (3 and 15%, respectively). Overall, there was a highly significant increase in both LAV and LVM (Table  1) , whereas mwFS showed an opposite trend. On univariate analysis, changes in LAV were directly related to changes in LVM (r ϭ 0.18, P ϭ 0.01) but unrelated to changes in mwFS (r ϭ Ϫ0.07, P ϭ 0.34). The distribution of LAV changes in the whole study cohort is described in Figure 1 .
Changes in LAV and Incident Fatal and Nonfatal CV Events: Univariate Analysis
After the second echocardiographic study, 76 patients died (52 [68%] of CV causes) and 33 had nonfatal CV events. Changes in LAV did not differ in patients who died and in those who survived (P ϭ 0.64). However, the rate of increase in LAV was significantly higher (P Ͻ 0.001) in patients with incident fatal and nonfatal CV events (median 0.59 ml/height 2.7 per yr; interquartile range 0.00 to 2.62 ml/height 2.7 per yr) than in event-free patients (median 0.11 ml/height 2.7 per yr; interquartile range Ϫ0.27 to 0.58 ml/height 2.7 per yr), and in a Kaplan-Meier analysis, patients with a relatively higher rate of increase in LAV (i.e., those with changes in LAV Ͼ75th percentile) had a relative risk for fatal and nonfatal CV events that was approximately two times higher (hazard ratio [HR] 1.85; 95% confidence interval [CI] 1.38 to 2.47) than that of the remaining patients (log rank test 23.1; P Ͻ 0.001). In a Cox regression analysis, changes in LVM (HR [1-g/m 2.7 per yr increase) 1.03; 95% CI 1.01 to 1.05; P ϭ 0.03) and changes in mwFS (HR [1%/yr increase] 0.86; 95% CI 0.75 to 0.99; P ϭ 0.04), as adjusted for corresponding baseline values, was significantly associated with incident fatal and nonfatal CV events. Of note, the rate of increase in LAV provided prognostic information for fatal and nonfatal CV events beyond that provided by LVM because changes in LAV predicted CV outcomes also in an analysis that was stratified according to the 75th percentile of LVMI (Figure 2 ).
Changes in LAV and Incident Fatal and Nonfatal CV Events: Multiple Cox Regression Analyses
The independent association between changes in LAV and fatal and nonfatal CV events was analyzed in a multiple Cox regression model taking into account a series of potential confounders, including baseline LAV (to avoid the statistical phenomenon of the regression to the mean) and LVM and LV geometry. In these models, changes in LAV, as a continuous variable or as dichotomized according to the 75th percentile of the corresponding data distribution, maintained an independent association and a highly significant one with incident CV outcomes ( Table 2 ). Of note, in this analysis, a 1-ml/m 2.7 per yr increase in LAV was associated with a 12% increase in the relative risk for fatal and nonfatal CV events. The association between changes in LAV and incident fatal and nonfatal CV outcomes remained unmodified (HR [1-ml/m 2.7 per yr increase in LAV] 1.12; 95% CI 1.05 to 1.20; P Ͻ 0.001) also after the inclusion of changes in LVM and LV function in the Cox model. Changes in LAV had an independent association with CV outcomes also when the crude (unindexed) estimate of LAV was entered in the same model instead of the height 2.7 estimate (HR [1-ml/yr increase in unindexed LAV] 1.03; 95% CI 1.01 to 1.05; P ϭ 0.001).
Discussion
This study shows that progressive increase in LAV predicts incident CV events in dialysis patients independent of the Figure 2 . Stratified Kaplan-Meier analysis for fatal and nonfatal cardiovascular events of changes in LAV in patients below and above the 75th percentile of left ventricular mass (LVM). To assess the functional form of LVM index (LVMI) better related to survival analysis (i.e., LVMI dichotomized according to the mean, the median, and the 75th percentile of the relative data distribution), we used the Martingale residuals analysis (23) . By this analysis, we found that the "75th percentile" was the most appropriate functional form of LVMI to be considered for the stratified analysis reported in this figure. corresponding baseline measurement of LAV and of LVM and LV function. This finding indicates that monitoring LA size by echocardiography provides independent prognostic information in patients with ESRD, thereby underscoring the relevance of repeated measurements of this echocardiographic measurement in the clinical management of these patients. LA enlargement is a hitherto overlooked component of the complex echocardiographic alterations that are observed in ESRD. In a recent study, we found that LAV is substantially higher in dialysis patients than in age-and gender-matched healthy individuals and that LVH and systolic dysfunction are major correlates of LA size in this population (12) . Of note, we also found that LAV predicts incident CV events independent of traditional and nontraditional risk factors and of LVM and LV function (12) . This finding indicates that the study of the left atrium may provide not only important anatomic details that are useful in interpretation of cardiomyopathy in ESRD but also complementary prognostic information for risk stratification in this condition. These observations are of relevance because populations with a high rate of CV complications, such as the ESRD population, demand not only baseline risk stratification but also periodic risk monitoring. To be useful for risk monitoring, clinical indicators should not only predict the outcome but also be sensitive to changes in risk that may occur over time as a consequence of disease progression or regression. Echocardiography-derived indicators provide important information for risk monitoring because worsening in LVM and in LV systolic function predicts an increase in the risk for death and CV events. Therefore, the issue of whether changes in LAV convey independent prognostic information for risk monitoring is a relevant question that needs to be specifically tested with repeated echocardiographic studies that adjust for LVM and LV function (the two major determinants of LA size in patients with ESRD). In this study, we observed a 10% increase in LAV in dialysis patients during a 15-mo interval, and changes in LAV were directly associated with changes in LVM but unrelated to changes in mwFS. Of note, changes in LAV were proportionally higher than those in LVM (ϩ7.6%) and LV a Forcing in Cox models heart rate, male gender, number of antihypertensive drugs, and changes in LVMI (i.e., the univariate correlates of LAV changes ͓P Յ 0.10͔) did not materially modify the strength of the association between fatal and nonfatal CV events and changes in LAV either expressed as a continuous variable (hazard ratio ͓HR; 1-ml/m 2.7 per yr increase͔ 1.18; 95% confidence interval ͓CI͔ 1.07 to 1.31; P ϭ 0.001) or as dichotomized according to the threshold of 1.68 ml/m 2.7 per yr (HR 2.64; 95% CI 1.53 to 4.54; P Ͻ 0.001). CAPD, continuous ambulatory peritoneal dialysis; HD, hemodialysis; LVH, left ventricular hypertrophy.
b The HR (and the 95% CI) associated with 1-SD increase in LAV changes (i.e., ϩ2.9 ml/m 2.7 per yr) was 1.38 (1.14 to 1.67; P Ͻ 0.001).
systolic function (Ϫ3.0%), indicating that LAV expansion progresses at a higher rate than other established echocardiographic indicators of high risk. Our prospective observations show that the rate of increase in LAV was substantially higher in patients who developed CV events than in event-free patients. Importantly, multivariate analysis indicated that changes in LAV had a prognostic power for CV outcomes beyond that provided by baseline LVM and LV function and by their changes during the follow-up. Therefore, LAV monitoring can be proposed as an adjunctive echocardiographic measurement that may refine risk monitoring in ESRD.
Two hypotheses are proposed to explain the independent prognostic value of changes in LAV. The first hypothesis rests on the several pathophysiologic links between LAV and coronary heart disease and circulatory overload (24) (links that may be even more pronounced in ESRD than in patients with other diseases). In other words, the predictive power of monitoring LAV may depend on this measurement's conveying prognostic information that is attributable to the evolution of underlying coronary artery disease and volume expansion, which are pervasive in ESRD. The second hypothesis is methodologic in nature. LAV is associated very strongly with LVH and with systolic dysfunction. In this perspective, the additional prognostic value of changes in LAV may depend on this measurement's capturing residual confounding as a result of the relatively imprecise echocardiographic estimation of LVM and LV function. Indeed, LAV as derived by the biplane method of discs (18) is more reproducible (i.e., more precise) than the most extensively used method of quantifying LVM (the M-mode based measurement [25] ). LVM as estimated by standard Mmode echocardiography is calculated on the basis of three variables (interventricular septum thickness, posterior wall thickness, and LV diameter) each of which has a measurement error. In contrast, LAV is estimated on the basis of an automatic computation that is based on LA contour reconstructing chamber volume, which minimizes measurement error (18) .
Our study has limitations. Because of early mortality and censoring, the cohort that we considered in the follow-up study had a lower CV risk than the original cohort (survival cohort bias). This explains why solid predictors of death and CV events in patients with ESRD, such as CRP and albumin, failed to predict incident CV outcomes beyond the time of the second echocardiographic study. However, we believe that it is of importance that LAV changes maintain a strong predictive power for CV events in a relatively low risk cohort, such as the cohort of patients who survived beyond the second echocardiographic study. The second limitation is the study design. Ours is an observational study, and, for this reason, the clinical usefulness of LAV monitoring remains to be assessed in interventional studies. Finally, new echocardiographic measurements allow LVM and LAV to be measured with considerable precision (26) . Reassessment of the problem with this new method will certainly refine the relative role of LVM and LAV in the risk assessment of patients with ESRD.
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